BioNTech AG acquires EUFETS AG
BioNTech AG announced the acquisition of all shares of EUFETS AG from Fresenius Biotech GmbH (Munich, Germany). EUFETS, formerly a fully owned subsidiary of Fresenius Biotech GmbH, is a specialist in GMP and GLP services for innovative biopharmaceutical approaches. Under the new owner, EUFETS will retain all facilities, employees and contractual obligations of the former company.
"The investment in EUFETS is an excellent fit endowing BioNTech with synergistic platforms and complementary expertise" commented Prof. Dr. Ugur Sahin, CEO of BioNTech AG, and Dr. Klaus Kühlcke, vice president operations of EUFETS, adding, "We are interested to progress EUFETS into a center of excellence that addresses the needs of individualized medicine by developing and providing a wide range of high-quality GMP/GLP services for innovative approaches such as recombinant vaccines, cell based therapies, gene- and immunotherapies.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.